Shares of Viking Therapeutics ( VKTX ) are rising after data from the company's latest weight loss drug trial showed greater efficacy compared to competing products from Eli Lilly and Company ( LLY ) and Novo Nordisk A/S ( NVO ). On Tuesday, the company also announced that it initiated an underwritten public offering of $350 million of shares of its common stock.